The core insight behind SynCraft is what the authors call the synthesis cliff. In medicinal chemistry, small structural changes can produce disproportionately large swings in synthetic feasibility, much as activity cliffs describe tiny modifications that dramatically alter biological potency. A molecule that is unreachable by any known reaction sequence may sit only one or two atom-level edits away from a close analogue that a retrosynthesis planner can route with ease. The trick, then, is not to abandon the original design and start over, but to find the minimal set of structural modifications that carries the molecule over the cliff while preserving everything that made it attractive in the first place: its binding interactions, its pharmacophore, its structural novelty.

Existing approaches to this problem tend to fall into two camps, and both come with costs. Post hoc filtering simply discards generated molecules that fail a synthesizability check, which wastes much of the creative output of generative models and biases libraries toward mundane chemistry. Projection-based methods go further, forcing an infeasible molecule onto the nearest point in a predefined space of synthetically accessible compounds. The problem is that this projection can wreck the very features that mattered. A key pharmacophore can be disrupted, a crucial hydrogen-bond donor can vanish, and the structural novelty that motivated the design in the first place can be flattened into something indistinguishable from existing patent literature. SynCraft rejects both strategies in favor of something more precise.

The framework reframes synthesizability optimization as a structural editing problem and hands that problem to a large language model, but with a crucial twist. Rather than asking the model to write out complete molecular structures as SMILES strings, a task at which language models are notoriously fragile because a single misplaced character can render an entire string chemically invalid, SynCraft asks the model to predict executable sequences of atom-level edits. Each edit is a discrete, verifiable operation on the existing structure, applied through cheminformatics tooling such as RDKit. This division of labor plays to the strengths of each component: the language model contributes chemical intuition and reasoning about which modifications are likely to help, while deterministic software guarantees that every edit is applied correctly and that the resulting molecule is always structurally valid.

To teach models this editing skill, the researchers assembled a training corpus of 3,332 molecular pairs, each accompanied by reasoning traces that explain why the edits transform an inaccessible molecule into a synthesizable one. The benchmarking results show that SynCraft outperforms state-of-the-art baselines at generating synthesizable analogues with high structural fidelity, meaning the edited molecules remain close to the original designs rather than drifting into unrelated chemical territory. Notably, the framework performed comparably whether it was running on proprietary frontier models or on open-weight backends, an important practical finding because it suggests the approach does not depend on access to the most expensive commercial systems. Laboratories with modest budgets can deploy the same chemistry on locally hosted models.

Perhaps the most striking validation of the approach is retrospective: SynCraft, guided by interaction-aware prompting that describes the protein-ligand contacts a molecule must preserve, successfully replicated the kind of editing judgments that expert medicinal chemists make intuitively. In tests on inhibitors of PLK1, a well-studied cancer target, the system’s proposed edits mirrored expert reasoning about which structural features to protect and which to sacrifice. The framework then went a step further into prospective territory, rescuing high-scoring RIPK1 candidate molecules that had been generated by earlier molecular generation models but discarded because they could not be synthesized. These were, in effect, good ideas trapped behind a synthetic wall, and SynCraft found the edits that let them through without destroying their binding profiles.

To make the workflow practical rather than merely demonstrative, the researchers packaged SynCraft as an agent skill, a modular capability that an autonomous AI agent can invoke. They demonstrated an end-to-end rescue workflow on candidate molecules generated for the SARS-CoV-2 main protease, the target that anchored much of the pandemic-era antiviral effort. The workflow verified that edited molecules retained their binding modes, checking interaction preservation with tools such as the protein-ligand interaction profiler, so that the rescue operation could be audited at the level of individual hydrogen bonds and hydrophobic contacts rather than trusted on faith. This kind of verification matters in a field where black-box outputs have historically been greeted with justified skepticism by experimentalists.

The broader significance of the work lies in how it repositions large language models within chemistry. Much of the early excitement, and disappointment, around LLMs in molecular design came from attempts to have them generate molecules directly, treating chemical structures as just another text format. The results were often syntactically broken or chemically nonsensical, and studies measuring the robustness of chemical language models to different molecular representations revealed how brittle the approach was. SynCraft belongs to a more mature second wave in which the language model serves as a reasoning engine over structured, tool-verifiable operations, a pattern that echoes the chain-of-thought techniques that unlocked reasoning in general-purpose models. The model thinks; deterministic chemistry software acts; validators check the result.

Accessibility may prove as consequential as accuracy. The SynCraft implementation, reproduction scripts for every experiment, and the agentic skill package have been released under an MIT license on GitHub, with the test sets, training corpus, inference outputs and case-study structures deposited openly on Figshare. Any group running generative drug design pipelines can therefore bolt synthesizability rescue onto their existing workflow without licensing barriers. As generative models continue to flood virtual screening campaigns with candidates, the gap between what AI can imagine and what chemists can build has been the field’s most persistent embarrassment. A framework that closes that gap with minimal, principled edits, while preserving the binding interactions that make a molecule worth making, turns discarded designs into a usable reservoir of drug candidates, and suggests that the future of AI-driven discovery lies less in generating more molecules than in knowing exactly which few atoms to change.

Subject of Research: Using large language models to optimize the synthesizability of AI-generated drug candidate molecules through predicted structural edit sequences

Article Title: Guiding large language models to predict edit sequences for molecular synthesizability optimization

Article References: Li, J., & Lai, L. (2026). Guiding large language models to predict edit sequences for molecular synthesizability optimization. Nature Machine Intelligence. https://doi.org/10.1038/s42256-026-01304-x

Image Credits: AI Generated

DOI: 10.1038/s42256-026-01304-x

Keywords: large language models, molecular synthesizability, drug discovery, generative AI, medicinal chemistry, SynCraft, molecular editing, retrosynthesis, SARS-CoV-2 main protease, RIPK1, PLK1, cheminformatics

The motivation for the work stems from a simple but uncomfortable observation. Although AI-assisted synthesis planning has proliferated across the chemical and pharmaceutical industries in recent years, a detailed understanding of how and why these systems fail has never been achieved. According to the authors, current models still struggle with predicting less frequent yet strategically critical reactions, and they continue to produce hallucinated, incorrect predictions that are fundamentally misaligned with chemists’ expectations. For a discovery chemist weighing whether to trust a model’s suggestion, such failures are not merely inconvenient; they can derail weeks of planning and undermine confidence in computational tools altogether.

The core of the new system rests on two newly developed model components with what the researchers describe as complementary inductive biases. Inductive biases are the built-in assumptions a model makes about the structure of the problem it is learning, and in chemistry these assumptions matter enormously. One component may excel at capturing the local, rule-like transformations that dominate reaction databases, while another is better positioned to generalize to sparse, unusual reaction classes where such rules break down. By pairing architectures whose strengths and blind spots differ in a structured way, the team ensured that the ensemble’s errors would be less correlated than those of any single model.

Crucially, however, simply averaging predictions from different architectures is not enough, because the outputs of retrosynthesis models are discrete chemical transformations rather than continuous scores. The researchers therefore introduced a novel, learning-based ensembling strategy that integrates the diverse components. Rather than treating the ensemble as a post-hoc投票 mechanism, the approach learns how to weigh and combine candidate predictions in a way that reflects chemical validity and likelihood. This design allows RetroChimera to draw on the complementary knowledge embedded in each constituent model without letting the weaknesses of one corrupt the strengths of the other.

The experimental evaluation was deliberately broad, spanning several orders of magnitude in data scale, and the results point to robustness that previous systems lacked. RetroChimera outperformed leading baselines across the benchmark settings tested, and it demonstrated the ability to learn from very small numbers of examples per reaction class. This latter capability addresses one of the most persistent pain points in machine learning for chemistry: the long tail of the reaction literature. Highly unusual transformations, such as those used to forge complex molecular frameworks in natural product synthesis or to install challenging stereochemical motifs, are chronically underrepresented in public databases, yet they are often the exact steps that determine whether an ambitious synthesis route is feasible at all.

The team also subjected the model to tests of generalization outside its training data, a regime in which many deep learning systems collapse into confident nonsense. RetroChimera’s predictions remained reliable under distribution shift, suggesting that the combination of diverse inductive biases and learned ensembling confers a form of robustness that single-architecture models have not matched. The researchers frame this as a demonstration of the viability of deep learning for accurate synthesis prediction in increasingly challenging regimes, where the easy, well-documented reactions that dominate benchmarks are no longer representative of the problems chemists face.

Perhaps the most consequential validation, however, came not from automated benchmarks but from human experts. Using both pairwise and pointwise evaluation setups, the researchers asked organic chemists to compare RetroChimera’s predictions against published reference reactions and against the outputs of other AI models. In these blind assessments, the chemists systematically preferred the suggestions generated by RetroChimera. That preference for model output over the actual published record of real reactions is a striking result, because it indicates the system can propose transformations that experts judge more sensible or more practical than the routes that chemists historically chose and journals published.

To test whether these gains survive contact with industrial reality, the team performed zero-shot transfer and fine-tuning experiments on internal datasets from two major pharmaceutical companies. These proprietary datasets differ from public reaction corpora in both scale and character, reflecting the molecule types, reaction conditions, and strategic priorities of real drug discovery programs. RetroChimera showed robust generalization under this distribution shift, performing well without any additional training in the zero-shot setting and improving further when fine-tuned on internal data. For pharmaceutical companies that have long been skeptical of benchmarks built on public data alone, this industrial validation may prove as important as any academic result.

The collaboration itself reflects the interdisciplinary demands of the problem. The author list spans machine learning researchers specializing in molecular AI, computational chemists embedded in industrial research organizations, and practicing medicinal and synthetic chemists at GSK, Novartis, and other partner organizations. Equal contributions are credited to Krzysztof Maziarz, Guoqing Liu, and Felix Pultar of Microsoft Research AI for Science, with corresponding authorship shared with Marwin H. S. Segler, who has worked on AI-driven synthesis planning for nearly a decade. Representatives from GSK’s discovery sciences group in Stevenage and Wuppertal-based chemist Mario P. Wiesenfeldt round out a team designed to ensure that evaluation criteria mirrored the judgments of working chemists rather than proxy metrics alone.

Looking ahead, the work suggests a broader lesson for applying AI in the natural sciences: progress may depend less on scaling a single architecture than on deliberately designing and combining models with different, complementary biases. As chemical synthesis remains a critical bottleneck in the discovery and manufacture of functional small molecules, tools that align with expert intuition while generalizing beyond the training literature could reshape how new medicines, materials, and agrochemicals are planned. If systems like RetroChimera continue to earn the trust of the chemists who use them, the long-promised collaboration between artificial intelligence and synthetic chemistry may finally be moving from demonstration to daily practice.

Subject of Research: Chemist-aligned AI retrosynthesis planning using ensembles of diverse inductive bias models

Article Title: Chemist-aligned retrosynthesis by ensembling diverse inductive bias models

Article References: Maziarz, K., Liu, G., Pultar, F., Gardner, J., Gensch, T., Helie, J., Misztela, H., Tripp, A., Li, J., Kornev, A., Gaiński, P., Hoefling, H., Fortunato, M., Gupta, R., Baxter, A., Poole, D. L., Elward, J. M., Krzyzanowski, A., Pogány, P., … Segler, M. H. S. (2026). Chemist-aligned retrosynthesis by ensembling diverse inductive bias models. Nature. https://doi.org/10.1038/s41586-026-11160-9

Image Credits: AI Generated

DOI: 10.1038/s41586-026-11160-9

Keywords: retrosynthesis, artificial intelligence, synthesis planning, machine learning, ensembles, inductive bias, chemical synthesis, pharmaceutical discovery, cheminformatics, deep learning, distribution shift, RetroChimera